Bacterial Skin Infections Therapeutics
1. Altabax patent expiration
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7875630 | ALMIRALL | Process salts compositions and use |
Feb, 2027
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43390 | ALMIRALL | Pleuromutilin derivatives as antimicrobials |
Apr, 2021
(4 years ago) | |
| USRE39128 | ALMIRALL | Pleuromutilin derivatives as antimicrobials |
Apr, 2021
(4 years ago) | |
| US8207191 | ALMIRALL | Process, salts, composition and use |
Aug, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2012 |
Drugs and Companies using RETAPAMULIN ingredient
NCE-1 date: 13 April, 2011
Market Authorisation Date: 12 April, 2007
Dosage: OINTMENT
More Information on Dosage
ALTABAX family patents
2. Xepi patent expiration
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(6 years from now) | |
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Dosage: CREAM
More Information on Dosage
XEPI family patents